Principal Financial Group Inc. Sells 1,182 Shares of Nurix Therapeutics, Inc. (NASDAQ:NRIX)

Principal Financial Group Inc. lowered its stake in shares of Nurix Therapeutics, Inc. (NASDAQ:NRIXFree Report) by 8.4% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 12,953 shares of the company’s stock after selling 1,182 shares during the period. Principal Financial Group Inc.’s holdings in Nurix Therapeutics were worth $190,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of the stock. ARK Investment Management LLC lifted its stake in Nurix Therapeutics by 23.2% during the 4th quarter. ARK Investment Management LLC now owns 3,194,999 shares of the company’s stock valued at $32,972,000 after acquiring an additional 601,952 shares during the period. Vanguard Group Inc. lifted its stake in shares of Nurix Therapeutics by 0.8% in the 3rd quarter. Vanguard Group Inc. now owns 2,714,845 shares of the company’s stock worth $21,339,000 after purchasing an additional 22,804 shares during the period. Affinity Asset Advisors LLC lifted its stake in shares of Nurix Therapeutics by 176.0% in the 4th quarter. Affinity Asset Advisors LLC now owns 690,112 shares of the company’s stock worth $7,122,000 after purchasing an additional 440,112 shares during the period. Charles Schwab Investment Management Inc. lifted its stake in shares of Nurix Therapeutics by 9.4% in the 4th quarter. Charles Schwab Investment Management Inc. now owns 622,297 shares of the company’s stock worth $6,422,000 after purchasing an additional 53,721 shares during the period. Finally, Wellington Management Group LLP lifted its stake in shares of Nurix Therapeutics by 41.6% in the 4th quarter. Wellington Management Group LLP now owns 205,324 shares of the company’s stock worth $2,119,000 after purchasing an additional 60,271 shares during the period.

Insider Buying and Selling at Nurix Therapeutics

In other Nurix Therapeutics news, insider Christine Ring sold 1,596 shares of the stock in a transaction that occurred on Monday, June 3rd. The shares were sold at an average price of $17.01, for a total transaction of $27,147.96. Following the completion of the sale, the insider now directly owns 19,838 shares of the company’s stock, valued at approximately $337,444.38. The sale was disclosed in a legal filing with the SEC, which is available at this link. In related news, insider Christine Ring sold 1,596 shares of the firm’s stock in a transaction on Monday, June 3rd. The shares were sold at an average price of $17.01, for a total value of $27,147.96. Following the completion of the transaction, the insider now directly owns 19,838 shares of the company’s stock, valued at $337,444.38. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CFO Houte Hans Van sold 3,499 shares of the firm’s stock in a transaction on Thursday, May 2nd. The shares were sold at an average price of $12.83, for a total transaction of $44,892.17. Following the completion of the transaction, the chief financial officer now directly owns 68,333 shares of the company’s stock, valued at $876,712.39. The disclosure for this sale can be found here. Insiders sold a total of 16,549 shares of company stock valued at $271,888 in the last three months. 9.80% of the stock is currently owned by corporate insiders.

Nurix Therapeutics Price Performance

Shares of NRIX opened at $20.50 on Tuesday. Nurix Therapeutics, Inc. has a 1 year low of $4.22 and a 1 year high of $22.44. The company has a 50 day simple moving average of $16.59 and a two-hundred day simple moving average of $13.33. The firm has a market cap of $1.01 billion, a P/E ratio of -7.71 and a beta of 2.22.

Nurix Therapeutics (NASDAQ:NRIXGet Free Report) last announced its quarterly earnings data on Wednesday, April 10th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.80) by $0.04. Nurix Therapeutics had a negative net margin of 178.93% and a negative return on equity of 67.08%. The business had revenue of $16.59 million during the quarter, compared to analyst estimates of $14.58 million. On average, sell-side analysts anticipate that Nurix Therapeutics, Inc. will post -2.85 earnings per share for the current year.

Analyst Ratings Changes

Several brokerages have recently weighed in on NRIX. Stephens began coverage on shares of Nurix Therapeutics in a research note on Tuesday, May 14th. They issued an “overweight” rating and a $20.00 price objective on the stock. Needham & Company LLC reiterated a “buy” rating and issued a $31.00 price objective on shares of Nurix Therapeutics in a research note on Monday, June 17th. HC Wainwright increased their price objective on shares of Nurix Therapeutics from $19.00 to $26.00 and gave the stock a “buy” rating in a research note on Tuesday, June 18th. JPMorgan Chase & Co. raised their target price on shares of Nurix Therapeutics from $30.00 to $31.00 and gave the stock an “overweight” rating in a research note on Monday, June 17th. Finally, Piper Sandler restated an “overweight” rating and set a $35.00 target price on shares of Nurix Therapeutics in a research note on Wednesday, June 5th. One investment analyst has rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $25.10.

View Our Latest Stock Report on Nurix Therapeutics

Nurix Therapeutics Company Profile

(Free Report)

Nurix Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and cell therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-2127, an orally bioavailable Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies; NX-5948, an orally bioavailable BTK degrader for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor for immuno-oncology indications.

See Also

Want to see what other hedge funds are holding NRIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nurix Therapeutics, Inc. (NASDAQ:NRIXFree Report).

Institutional Ownership by Quarter for Nurix Therapeutics (NASDAQ:NRIX)

Receive News & Ratings for Nurix Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nurix Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.